Pricing Log in Create free account
Saturday 17 October 2026 Export GKOS’s income statement to Excel — free account

Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024. In the quarter to June 2026, revenue grew 49.5%, EPS grew 8.82%, free cash flow grew 211.8% and total debt fell 2.15%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

164.84 0.76 −0.46%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
−139×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 69.31
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 2 1 4 1 4 2 4 1 5 4 2 1
Insider Ownership 3.70%

Capital & Financial Ratios $m

Market Cap 9,770.00
Revenue 612.84
Net Income (188.05)
Free Cash Flow (12.20)
Net Debt (218.88)
Current Ratio 5.04 (at or above 1.5: strong)
Debt/Equity 0.10 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (139.00) (negative: loss-making)
P/S ratio 15.82 (above 10: high)
P/B ratio 14.21 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 65.84% (at or above 15%: strong)
Next Y EPS Growth 270.69% (at or above 15%: strong)
Next Y revenue growth 36.31% (at or above 10%: strong)
Next 5Y EPS Growth 51.45% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 15.9×, against a ten-year median of 10.9×; over the ten years it ranged from 2.8× in 2016 to 22.3× in 2024.
P/S against its own 10 years 87.91%
10-year low 10-year high
P/B against its own 10 years 94.66%
10-year low 10-year high
EV/Sales against its own 10 years 87.95%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 295 319 279 286
Receivables 40 61 109 139
Inventory 42 58 64 59
Other — — — —
395 450 475 516
2023 2024 2025 Q'26
Payables 13 13 25 19
ST’ Debt — — — —
Other — — — —
74 75 101 102

Compound Annual Growth %

10y 5y 3y
Sales 21.61% 17.67% 21.51%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 21.29% (0.34%) 7.38%

Revenue $m

Mar Jun Sep Dec Year
’26 151 186 — — —
’25 107 124 134 143 507
’24 86 96 97 105 383
’23 74 80 78 82 315
’22 68 73 71 71 283
’21 68 78 75 73 294
’20 55 32 65 73 225
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) 15 — — —
’25 (19) 7 (10) 7 (15)
’24 (34) (18) (10) 1 (61)
’23 (31) (8) (8) (11) (58)
’22 10 (12) (27) (4) (33)
’21 4 7 18 (5) 25
’20 (13) (11) (10) 11 (23)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) 12 — — —
’25 (20) (11) (12) 4 (39)
’24 (35) (20) (11) (1) (68)
’23 (38) (14) (12) (15) (78)
’22 3 (22) (33) (12) (63)
’21 (13) (4) 8 (14) (23)
’20 (14) (14) (11) 8 (30)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.34) (0.31) — — —
’25 (0.32) (0.34) (0.28) (2.32) (3.28)
’24 (0.82) (1.06) (0.39) (0.60) (2.77)
’23 (0.72) (0.68) (0.63) (0.75) (2.78)
’22 0.11 (0.96) (0.58) (0.66) (2.09)
’21 (0.36) (0.38) 0.13 (0.47) (1.07)
’20 (1.24) (0.90) (0.35) (0.24) (2.70)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 14.25 23.08 25.25 50.60 23.31 39.35 33.33 42.48 74.75 73.16

Analyst estimates 2026–2028

Powerpack
High 39.82 52.49 70.91 84.65 76.20 99.00 64.49 86.53 153.50 163.71
People
People Employees 264 387 437 600 653 727 783 907 995 1,094
Revenue/emp, $m 0.43 0.41 0.41 0.39 0.34 0.40 0.36 0.35 0.39 0.46
Income, $m
Income, $m Revenue 114 159 181 237 225 294 283 315 383 507
Gross margin, % 85.86 86.78 86.17 83.72 59.23 77.34 75.61 75.99 75.48 77.97
EBT 5 0 (12) (50) (132) (49) (98) (134) (146) (193)
EBT margin, % 3.99 0.00 (6.82) (21.11) (58.82) (16.76) (34.80) (42.49) (37.97) (38.04)
Net income 5 0 (13) 15 (120) (50) (99) (135) (146) (188)
Depreciation 5 6 6 14 66 37 38 38 37 39
Per share, $
Per share, $ Revenue 3.47 4.63 5.13 6.34 5.06 6.33 5.96 6.50 7.27 8.87
Earnings 0.14 0.00 (0.37) 0.41 (2.70) (1.07) (2.09) (2.78) (2.77) (3.28)
Cash flow 0.37 0.76 0.53 (0.01) (0.52) 0.53 (0.70) (1.19) (1.16) (0.26)
Capex (0.19) (0.18) (0.29) (0.13) (0.16) (1.03) (0.63) (0.42) (0.12) (0.42)
Free cash flow 0.18 0.58 0.24 (0.14) (0.67) (0.50) (1.33) (1.61) (1.28) (0.68)
Book value 3.56 4.02 4.92 18.02 15.00 12.65 11.17 9.53 14.54 11.47
Shares, m 33 34 35 37 44 46 47 48 53 57
Valuation, ×
Valuation, × P/E 253.15 0.00 0.00 160.21 0.00 0.00 0.00 0.00 0.00 0.00
P/S 9.71 5.85 10.94 8.59 14.89 7.02 7.36 11.86 20.63 12.73
P/B 9.47 6.74 11.41 3.02 5.02 3.51 3.93 8.08 10.31 9.84
EV/Sales 8.90 5.12 10.19 8.11 14.21 7.76 8.35 12.93 20.71 12.86
EV/FCF 168.84 41.25 216.06 (377.22) (106.79) (98.86) (37.38) (52.18) (117.49) (167.07)
Cash, $m
Cash, $m Operating cash flow 12 26 19 0 (23) 25 (33) (58) (61) (15)
Capex (6) (6) (10) (5) (7) (48) (30) (20) (6) (24)
Free cash flow 6 20 9 (5) (30) (23) (63) (78) (68) (39)
Balance, $m
Balance, $m Working capital 103 123 146 205 420 423 372 321 375 374
Total debt — — — 58 250 353 354 353 69 68
Net debt (96) (119) (140) (116) (154) (61) 1 58 (249) (211)
Shareholders’ equity 117 138 174 673 667 587 530 462 767 656
Returns, %
Returns, % ROA 3.60 (0.06) (6.95) 3.01 (13.20) (4.83) (9.67) (13.86) (15.29) (20.09)
ROIC 12.37 (7.43) (24.35) (5.64) (15.05) (3.91) (9.69) (15.48) (14.78) (28.00)
ROE 4.26 (0.07) (8.30) 3.64 (17.95) (7.91) (17.76) (27.16) (23.83) (26.38)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Glaukos Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PEN Penumbra, Inc. $12.7B 78.4× 63.5× +14.90% (above 0%: growing) −24.79% (below 0%: shrinking) +10.81% (above 0%: growing) 67.93% 10.52% Compare
SNN Smith & Nephew SNATS, Inc. $12.2B 35.4× 18.6× +7.99% (above 0%: growing) −14.23% (below 0%: shrinking) +293.94% (above 0%: growing) 69.42% 0.00% Compare
GMED Globus Medical, Inc. $10.6B 19.3× 20.3× +5.94% (above 0%: growing) −25.33% (below 0%: shrinking) +571.30% (above 0%: growing) 69.42% 23.10% Compare
BIO.B Bio-Rad Laboratories, Inc. $10.3B 43.7× — −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15% Compare
GKOS Glaukos Corporation $9.8B — (loss-making) — (loss-making) +49.54% (above 0%: growing) n/m +211.83% (above 0%: growing) 81.67% (9.30%)
BIO Bio-Rad Laboratories, Inc. $9.8B 42.5× 35.4× −0.09% (below 0%: shrinking) +19.02% (above 0%: growing) −6.06% (below 0%: shrinking) 53.12% 11.15% Compare
PODD Insulet Corporation $9.6B 26.4× 24.7× +23.51% (above 0%: growing) +328.13% (above 0%: growing) −70.51% (below 0%: shrinking) 70.18% 16.18% Compare
BRKR Bruker Corporation $8.6B — (loss-making) 55.7× +5.15% (above 0%: growing) n/m +28.63% (above 0%: growing) 49.61% (7.79%) Compare
HAE Haemonetics Corporation $5.5B 57.7× 18.0× +5.60% (above 0%: growing) +2.86% (above 0%: growing) +220.38% (above 0%: growing) 59.76% 16.93% Compare
Median of peers $10.0B 42.5× 24.7× +5.77% +2.86% +19.72% 63.85% 11.15%

All 149 Medical Devices stocks →

Glaukos Corporation (GKOS) key facts

  • Strength: Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
  • Glaukos Corporation (GKOS) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, GKOS traded at $164.84, a market capitalization of $9.8 billion.
  • Return on equity was −26.4% and debt-to-equity 0.10.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 15.20 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Glaukos Corporation (GKOS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/GKOS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com